Sutro Biopharma (NASDAQ:STRO) Issues Quarterly Earnings Results

Sutro Biopharma (NASDAQ:STRO) released its quarterly earnings data on Thursday. The company reported ($2.96) earnings per share for the quarter, RTT News reports. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%.

Sutro Biopharma Trading Down 6.7 %

NASDAQ:STRO traded down $0.09 on Thursday, hitting $1.25. 806,080 shares of the stock were exchanged, compared to its average volume of 924,303. The stock has a market cap of $103.07 million, a PE ratio of -0.78 and a beta of 1.22. Sutro Biopharma has a fifty-two week low of $1.25 and a fifty-two week high of $6.13. The stock has a fifty day moving average of $1.79 and a 200-day moving average of $2.79.

Wall Street Analyst Weigh In

STRO has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Wells Fargo & Company dropped their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.